Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZGIPC
ADC Name
CM311-18A9-VH7/VL2-ADC
Synonyms
CM311-18A9-VH7/VL2-ADC
   Click to Show/Hide
Organization
SHANGHAI MIRACOGEN INC. | KEYMED BIOSCIENCES CO., LTD
Drug Status
Investigative
Drug-to-Antibody Ratio
3
Structure
Antibody Name
CM311-18A9-VH7/VL2
  Antibody Info 
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
111.1
ng/mL
CVCL_8891
Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis
Half Maximal inhibitory Concentration (lC50) 
155.5
ng/mL
CVCL_8891
Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis
Half Maximal inhibitory Concentration (lC50) 
4045
ng/mL
CVCL_0186
Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 111.1 ng/mL Moderate Claudin 18.2 expression (Claudin 18.2++)
Method Description
LT-1C8 at 5000 or 10000 cells/well, 0.7mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
In Vitro Model Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis LT-1C8 cells CVCL_8891
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 155.5 ng/mL High Claudin 18.2 expression (Claudin 18.2 +++)
Method Description
LI-M11 cells at 5000 cells/well, 0.7mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
In Vitro Model Lung lymphangioleiomyomatosis, Lymphangioleiomyomatosis LI-M11 cells CVCL_8891
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 4045 ng/mL Negative Claudin 18.2 expression (Claudin 18.2-)
Method Description
BxPC-3 at 3000 cells/well, 0.7mg/ml ADCs were added and incubated for 96 hours, then CCK-8 or Presto-Blue detection reagent was added to each well, and a microplate reader was used for detection and four parameter fitting was carried out.
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
References
Ref 1 Antibody-drug conjugate and application thereof